RCS - Spexis AG - Annual General Meeting 2022
01/04/2022 09:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220401:nRSA9251Ga&default-theme=true
RNS Number : 9251G Spexis AG 01 April 2022
Spexis AG / Key word(s): AGMEGM
Spexis publishes invitation to Annual General Meeting 2022
01-Apr-2022
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, April 1, 2022
Spexis publishes invitation to Annual General Meeting 2022
- Pre-AGM information call on April 7, 2022 at 2:30PM CET
- AGM to be held April 26, 2022
- Shareholders not physically present, in accordance with COVID-19 ordinances
Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company, focused on
rare diseases and oncology with an initial focus on chronic respiratory
diseases today published the invitation to its Annual General Meeting on April
26, 2022.
As a precautionary and prudent measure, the Board of Directors has decided to
conduct the Annual General Meeting 2022 without the physical presence of
shareholders, in accordance with Article 8 of the Federal Act on the Statutory
Principles for Federal Council Ordinances on Combating the COVID-19 Epidemic
(COVID-19 Act) and Article 27 of Ordinance 3 on Measures to Combat the
Coronavirus (COVID-19) (COVID-19 Ordinance 3).
The company will be seeking to maximize the number of shareholders executing
their voting rights and will host a pre-AGM information call on April 7, 2022
at 2:30PM CET. Investors are invited to submit questions in advance by email
to IR@spexisbio.com (mailto:IR@spexisbio.com) . To access the earnings call,
please use the following details:
France: +33 (0)1 70 730 3 39
Germany: +49 (0)69 22222 5197
Italy: +39 02 3602 6066
Switzerland +41 (0)44 580 7279
United Kingdom +44 (0)330 165 4012
United States +1 646-828-8073
Event Title: Spexis AG - Annual General Meeting Information Call 2022
Confirmation code: 3315627
The presentation will also be available via webcast:
https://www.webcast-eqs.com/spexis20220407/no-audio
(https://che01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.webcast-eqs.com%2Fspexis20220407%2Fno-audio&data=04%7C01%7CHernan.Levett%40spexisbio.com%7Cd5306afa257041fb082808da0b601a97%7Cc13de0c0b4d3464c93a923fcbc19b97f%7C0%7C0%7C637834804689784548%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=vHOXSFwynu%2BhuLSI%2FKuHqRB8OmJMPrXM7ai3%2Fz0DjiM%3D&reserved=0)
Link for participants of the conference call (only slides, no audio, no
delay): https://www.webcast-eqs.com/spexis20220407/no-audio
(https://che01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.webcast-eqs.com%2Fspexis20220407%2Fno-audio&data=04%7C01%7CHernan.Levett%40spexisbio.com%7Cd5306afa257041fb082808da0b601a97%7Cc13de0c0b4d3464c93a923fcbc19b97f%7C0%7C0%7C637834804689784548%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=vHOXSFwynu%2BhuLSI%2FKuHqRB8OmJMPrXM7ai3%2Fz0DjiM%3D&reserved=0)
After the call, the presentation will be available via the above link.
For further information please contact:
For Investors: For Media:
Hernan Levett
Dr. Stephan Feldhaus
Chief Financial Officer
Feldhaus & Partner
Spexis AG.
+41 79 865 92 56
+41 61 567 16 00 feldhaus@feldhaus-partner.ch (mailto:feldhaus@feldhaus-partner.ch)
IR@spexisbio.com (mailto:IR@spexisbio.com)
About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland, focused on rare diseases and oncology. The current pipeline of
the company is a combination of two legacy companies, Polyphor AG and
EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
under the symbol SIX:SPEX. For further information please visit:
www.spexisbio.com (http://www.spexisbio.com/) .
Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
Additional features:
File: Spexis AGM invitation
(https://eqs-cockpit.com/c/fncls.ssp?u=fa93dabc759bb8bd35b5445ce10497e9)
End of ad hoc announcement
About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland, focused on rare diseases and oncology. The current pipeline of
the company is a combination of two legacy companies, Polyphor AG and
EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
under the symbol SIX:SPEX. For further information please visit:
www.spexisbio.com (http://www.spexisbio.com/) .
Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
Additional features:
File: Spexis AGM invitation
(https://eqs-cockpit.com/c/fncls.ssp?u=fa93dabc759bb8bd35b5445ce10497e9)
End of ad hoc announcement
Language: English
Company: Spexis AG
Hegenheimermattweg 125
4123 Allschwil
Switzerland
Phone: +41 61 567 1600
Fax: +41 61 567 1601
E-mail: info@spexisbio.com
Internet: www.spexisbio.com
ISIN: CH0106213793
Valor: SPEX
Listed: SIX Swiss Exchange
EQS News ID: 1317395
End of Announcement EQS News Service
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAGLGDSCUGDGDB